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We have recently reported that rats with complete thoracic spinal cord injury (SCI) that
received a combinatorial treatment, including viral brain-derived neurotrophic factor (BDNF)
delivery in the spinal cord, not only showed enhanced axonal regeneration, but also dete-
rioration of hind-limb motor function. By demonstrating that BDNF over-expression can
trigger spasticity-like symptoms in a rat model of sacral SCI, we proposed a causal rela-
tionship between the observed spasticity-like symptoms (i.e., resistance to passive range
of motion) and the over-expression of BDNF. The current study was originally designed to
evaluate a comparable combined treatment for cervical SCI in the rat to improve motor
recovery. Once again we found similar signs of spasticity involving clenching of the paws
and wrist flexion.This finding changed the focus of the study and, we then explored whether
this spasticity-like symptom is directly related to the over-expression of BDNF by adminis-
tering a BDNF antagonist. Using electromyographic measurements we showed that this
treatment gradually diminished the resistance to overcome forelimb flexion in an acute
experiment. Thus, we conclude that neuro-excitatory effects of chronic BDNF delivery
together with diminished descending control after SCI can result in adverse effects.
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INTRODUCTION
Axonal regeneration in the adult mammalian central nervous
system is inhibited by numerous factors (1) impeding the devel-
opment of effective treatments for brain or spinal cord injuries
(SCI). Consequently, it is likely that repair of the injured spinal
cord by axonal regeneration and plasticity will require a com-
bined treatment approach. Several combinatorial strategies have
been pursued with a wide range of outcomes [e.g., Ref. (2–5)].
These experiments are not only technically demanding, but also
challenging in the interpretation of the results, considering the
unpredictable effects of promoting neurite outgrowth and possible
interactions between treatment components (6, 7).
One prominent molecule that has been the subject of many
studies in spinal cord repair is brain-derived neurotrophic factor
(BDNF). BDNF not only has neuro-protective, regeneration, and
plasticity promoting effects but also neuro-excitatory properties
and binds with high affinity to the TrkB receptor and with lower
affinity to p75 [reviewed in Ref. (8)]. As such, BDNF is a prominent
candidate for combined treatment approaches [e.g., Ref. (6, 9, 10)].
However, due to the broad range of its effects, the consequences of
BDNF delivery can be complex. For example, we observed that a
combinatorial treatment involving BDNF (achieved by direct viral
vector injection and bone marrow stromal cell grafts genetically
modified to express BDNF) promoted spasticity in rats with a cer-
vical hemisection. Because the combined treatment also promoted
axonal regeneration and plasticity, the origin of the observed spas-
ticity remains unclear (11). We could, however, provide an indirect
explanation by demonstrating that the over-expression of BDNF
could promote the development of hyperreflexia in tail muscles
in a sacral model of SCI (11). Yet, it remains unclear whether
this effect of BDNF was caused by its neuro-excitatory properties
or through an augmentation of neuroplasticity and/or regenera-
tive growth. However, this was not the original question of the
current study. We initially set out to test a combined treatment
that addressed multiple limitations for neurite growth follow-
ing cervical SCI. The focus of the analysis shifted when severe
spasticity-like symptoms in the injured forelimb became evident,
which led us to focus on determining the cause of spasticity. To
address this question we administered a BDNF antagonist into the
spinal cord of rats that showed spasticity-like symptoms, and these
were gradually reduced by this treatment.
MATERIALS AND METHODS
ANIMALS
Adult female Fischer 344 rats (Charles River, 180–220 g) were
group housed and kept at 12/12 h light/dark cycle with ad libi-
tum water. The study was approved by the Animal Care and Use
Committee for Health Sciences of the University of Alberta, and
complies with the guidelines of the Canadian Council for Animal
Care.
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LESION SURGERY AND TREATMENT
Rats were anesthetized (using Hypnorm 0.16 mg/kg; Vetapharma,
Leeds, UK; and Midazolam 2.5 mg/kg; Sandoz, Canada; diluted in
sterile water) and mounted into a stereotaxic frame (Kopf Instru-
ments), and the spinal cord between C5 and C6 was exposed by
performing a laminectomy of half of the C5 segment. The spinal
cord was lesioned using a microsuction pipette and a spring scissor.
A lateral hemisection lesion was performed ipsilateral to the pre-
ferred paw as determined by a forelimb reaching task. A small gap
was created to ensure lesion completeness and provide space for
the cell graft. The dura was sealed with a thin agarose film (Sigma)
and fibrin glue (Baxter, USA), overlying muscles were sutured and
the skin was stapled. Rats were placed on a heating pad until they
were awake and received buprenorphine (0.03 mg/kg) as analgesic
and saline over the next 2 days.
Preparation of cell grafts to provide a tissue bridge for regenerating
axons
Fibroblasts were isolated from skin biopsies of Fischer 344 rats and
cultivated in D’MEM/10% FBS with antibiotics. Cells were trans-
duced with retroviral vectors to express BDNF as described by Lu et
al. (11, 12) or NT-3 (13) and selected for G418 resistance. BDNF
and NT-3 expression was measured in vitro, in 24 h cell culture
supernatants by ELISA as described (14, 15). BDNF-transduced
fibroblasts expressed 27 ng/106 cells/24 h, NT-3 transduced cells
expressed 134 ng/106 cells/24 h. For grafting, BDNF and NT-3
expressing cells were mixed 1:1 and 2–3µl were injected into the
lesion site using a 5-µl Hamilton syringe at a concentration of
2.5× 104 cells/µl.
scAAV vector preparation and injections
Self-complementary adeno-associated viral vectors (scAAV) were
generated as described by Lu et al. (11). In order to attract regener-
ative growth out of the graft into the caudal spinal cord, BDNF, and
NT-3 (and GFP as control) transfected scAAV vectors (1.3µl/site)
were injected 1.25, 2.5, and 4 mm caudal to the lesion on the side
ipsilateral to the lesion through pulled glass capillaries using a
Picospritzer II similar to Lu et al. (11). The injection volume was
divided over a depth of 1 and 1.5 mm.
One week post-lesion surgery, cell grafts and viral vector injec-
tion surgeries were performed in all lesioned animals in the
following groups:
Group 1 is a CONTROL group used to demonstrate the ability
of self-complementary adeno-associated virus (scAAV) vectors to
successfully infect spinal neurons. This group did not receive a cell
graft, only PBS, followed by injections of 4.3× 1011 vg/ml scAAV
vectors expressing Green Fluorescent Protein (scAAV2-GFP) at
1.25, 2.5, and 4 mm caudal to the lesion; n= 16.
Group 2, scAAV-BDNF group received an injection of PBS in the
lesion site, followed by 4.3× 1011 vg/ml scAAV-BDNF injections
at 1.25, 2.5, and 4 mm caudal to the lesion to serve as trophic
support for regenerating fibers; n= 5.
Group 3, the GRAFT/BDNF/NT-3 or FULL treatment group,
received a fibroblast cell graft (expressing BDNF and NT-3) into
the lesion site to provide a permissive cellular matrix that allows
axonal growth,and a trophic stimulus to stimulate axonal growth.
This group also received injections of a mixture of scAAV2 BDNF
(f.c. 4.3× 1011 vg/ml), scAAV2-NT-3 (f.c. 4.3× 1011 vg/ml), and
scAAV2-GFP (f.c. 4× 1010 vg/ml) mixed with 20 U/ml ChABC
(Seigaku, USA) caudal to the lesion (1.25, 2.5, and 4 mm). The
neurotrophic mixture is intended to provide trophic stimu-
lus beyond the lesion and ChABC degrades growth inhibitory
proteoglycans in the scar tissue (3). In addition, this group
also received a subcutaneous injection of the phosphodiesterase
(PDE) inhibitor, Rolipram, (AG Scientific, San Diego, CA, USA;
3 ml of 3 mg/kg in 2% DMSO and saline) once per day for 14 days
following the lesion. This drug elevates cAMP levels in the CNS
and augments regeneration-related gene expression in injured
neurons (16); n= 18.
Group 4, the GRAFT/scAAV-NT-3 group received a fibroblast cell
graft expressing BDNF and NT-3 into the lesion site, injections of
scAAV expressing NT-3 and GFP only, mixed with ChABC caudal
to the lesion and subcutaneous injections of rolipram; n= 7.
Group 5, the GRAFT/ChABC group received a fibroblast cell graft
expressing BDNF and NT-3 into the lesion site and ChABC injec-
tions 1.25, 2.5, and 4 mm caudal to the lesion, followed by daily
rolipram administration; n= 5.
BEHAVIORAL TESTING
Single-pellet grasping task
This test was performed as described previously (17, 18). In
order to motivate rats to grasp for sugar pellets (45 mg, banana
flavor; TestDiet, Richmond, CA, USA) in the task, restricted
amounts of food were allowed directly after the daily train-
ing session (10 g/rat/day). A transparent Plexiglas chamber
(30 cm× 36 cm× 30 cm) with a narrow opening in the front wall
and an attached shelf outside (2 cm distance from the inside of the
front wall, 3 cm above the floor) was used. Pellets were placed at a
distance such that the rats had to grasp them with their preferred
forelimb and could not reach them with their tongue. The pre-
ferred paw was determined for each rat during the first few training
sessions. Successful grasps were scored over a 10-min period only
when a rat was able to grasp the presented pellet, bring it to its
mouth and eat it. Pre-operative baseline values were obtained after
a 4-week training period (five times per week,10 min per rat). Post-
operative rehabilitative training of the injured forelimb started
1 week after graft implantation surgery (2 weeks post-lesion).
Forelimb placement
To further assess forelimb function, all rats were scored over a 4-
min period in a Plexiglas open field according to Martinez et al.
(19), with scores ranging from 0 (no function) to 20 (no deficit).
Behavioral components were categorized from global fore- and
hind-limb movements to antero-posterior coordination, which
included weight support, fine distal positioning, and stepping
abilities. Nine weeks post-lesion, asymmetries in spontaneous
forelimb use were evaluated by placing individual rats into a clear
Plexiglas cylinder (24 cm high/19 cm inner diameter). A mirror
was placed underneath the cylinder at an angle to facilitate the
videotaping of the rat’s vertical exploratory activity in the cylin-
der (Figure 1). Ten rearing movements were recorded in each test
session. Each forepaw placement on the wall of the cylinder was
scored during a rearing movement. If the affected forepaw was
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FIGURE 1 |Treatments involving BDNF promoted exaggerated wrist
flexion and affected forelimb use. Signs of wrist flexion became apparent
as early as 2 weeks after treatment (A). By 9 weeks post-injury the cylinder
exploration task indicated that animals in the FULL treatment group and the
scAAV-BDNF only group had significantly reduced use of the injured
forelimb (*) when compared to control animals (B). Error bars show
average±SE; *p<0.05, **p<0.005, ***p<0.0005.
plantar on contact with the wall of the cylinder, the number of
contacts was multiplied by two, if only the dorsal surface of the
paw was placed on the wall, the number of contacts was multi-
plied by one and if the paw did not contact the wall a score of 0
was assigned, thus allowing for a maximum score of 20.
Grip strength
The grip strength of the forelimbs (or in other words, the force
needed to overcome wrist and digit flexion when actively or pas-
sively holding on to a bar) was assessed 9 weeks post-lesion by
measuring the maximum force (in gram) exerted by each forelimb,
with a Grip Strength Meter apparatus (Columbus Instruments,
OH, USA, Figure 2). For the final values, four readings for both
paws were obtained over three different trials and averaged for
post-operative analysis.
Sensory test
Forelimb withdrawal latency to a heat stimulus was measured prior
to injury (baseline) and 9 weeks post-lesion using methods previ-
ously described (20). Briefly, the rats were placed on a glass plate
over a light box, and a radiant heat stimulus (Ugo Basile) was
applied by aiming a beam of light onto the plantar surface of the
paw of each forelimb through the glass plate. The light beam was
turned off automatically when the rat lifted the limb, allowing
the measurement of time between the start of the light beam and
the paw withdrawal. Five minutes were allowed between three tri-
als, baseline values were averaged for each limb and compared to
post-injury values.
ELECTROPHYSIOLOGY
Electromyographic (EMG) recordings of flexor muscles of the
injured paw were carried out prior to perfusion. Animals were
anesthetized with 5% isoflurane gas anesthesia for induction and
FIGURE 2 | Brain-derived neurotrophic factor expression increases
wrist flexion: using an apparatus designed to measure grip strength
(A) we compared measurements between control animals and the rats
receiving scAAV-BDNF only or the FULL treatment (B). When compared
with the control group, a significant increase in “grip” strength was
observed in both the scAAV-BDNF and the FULL treatment groups at
9 weeks post treatment. The dashed line indicates a normal grip strength
value. Error bars show average±SE; **p< 0.01, ***p<0.001.
1.5% for maintenance of anesthesia and placed into a stereotaxic
frame. The spinal cord surrounding the hemisection lesion was
exposed. To record EMG responses during manual wrist extension,
two electrodes with exposed tips (Teflon coated wire; A-M Systems,
Carlsborg, WA, USA) were inserted into wrist flexors of the fore-
limb ipsilateral to the lesion. The EMG signal was amplified (Grass,
Astro-Med Inc., West Warwick, RI, USA), digitized (5 kHz, Digi-
data 1322A; Axon instruments, Foster City, CA, USA), and filtered
(30–300 Hz) as described earlier (17). The muscle responses were
recorded under anesthesia before and 10, 20, and 30 min follow-
ing injection of the TrkB antagonist, TrkB-Fc (1µl of 0.2 mg/ml;
Sigma) or saline into the spinal cord lesion site.
The following animals were selected for EMG analysis: (i) three
rats without signs of spasticity (one from the CONTROL group
and two from the FULL treatment group) received a TrkB-Fc injec-
tion. (ii) Four rats with spasticity (one from the scAAV-BDNF,
two from the FULL treatment group and one from GRAFT/NT-
3) received a saline injection only. (iii) Ten rats with spasticity
(two from scAAV-BDNF and eight from FULL treatment group)
received TrkB-Fc injection.
Electromyographic responses were recorded, and the burst
duration was measured using Axoscope software (Axoscope
9.0.1.16; Molecular Devices, Sunnyvale, CA, USA). The traces were
rectified and the average burst amplitude was quantified and then
multiplied by the burst duration using Microsoft Excel.
The animals were euthanized immediately following the
EMG recordings with pentobarbital (Euthanyl, Bimeda-MTC;
70/100 mg body weight) and transcardially perfused with
phosphate-buffered saline, followed by 4% paraformaldehyde
(PFA) in 0.1 M phosphate buffer, pH 7.4. The spinal cord
was removed, post-fixed in 4% PFA overnight at 4°C and
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cryo-protected in 30% sucrose over 2 days. The cervical enlarge-
ment encompassing the lesion site (C2–6) was embedded in Tissue
Tek (Sakura Finetek USA Inc., Torrance, CA, USA) and frozen in
2-methyl-butane at−60°C.
HISTOLOGY
Spinal cords were cryosectioned in the horizontal plane at 25µm
and mounted in eight series onto Fisherbrand slides (Fisher Sci-
entific, Ottawa, ON, Canada). To evaluate the lesion site, sections
were counterstained with 0.1% Cresyl Violet and dehydrated in
increasing alcohol concentrations, cleared with xylene, and cov-
erslipped with Permount (Fisher Scientific). Lesion sizes were
reconstructed from C2 to C6 spinal cord tissue by analyzing every
fourth section through the dorso-ventral plane of the spinal cord
by using central canal and gray/white matter interphases as land-
marks. From these reconstructions, the percent cross-sectional
surface area of the damaged tissue was measured using Image J
(NIH) software. Animals with lesions deviating from a complete
hemisection by >10% were removed from this study.
Immuno-histochemistry of serotonergic (5-HT) fibers was car-
ried out on every second horizontal section encompassing the
lesion site using rabbit anti 5-HT antibody (S5545, Sigma-Aldrich,
Oakville, ON, Canada). In brief, following a 10% normal goat
serum (NGS, Vector Labs, Burlingame, CA, USA) blocking step,
the slides were incubated in 1:1000 dilution of primary antibody
containing 1% NGS overnight at 4°C. The slides were then washed
in TBS before an overnight incubation at 4°C in the secondary
antibody (Vector Labs, Burlingame, CA, USA). Application of ABC
and DAB solutions according to manufacturer’s recommendations
followed (Vector Laboratories, Burlingame, CA, USA). After three
washing steps of 10 min in TBS, the slides were serially dehydrated
with alcohol, cleared with xylene, and coverslipped in Permount
(Sakura Finetek USA, Torrance, CA, USA).
The density of 5-HT fibers rostral and caudal of the lesion
was quantified from images taken at 400× using a Leica light
microscope. Images were saved as 8-bit gray-scale TIFF files and
imported into Image J software version 1.43q (NIH), where thresh-
old values were adjusted. Selected threshold values were kept
constant for all images to standardize the amount of background
included in quantification. Integrated density measurement, rep-
resenting the sum of the values of the pixels in an image, was
averaged from five different images.
STATISTICS
To determine statistical differences between treated and untreated
animals, Student’s t -test and a one-way ANOVA with Tukey’s hon-
estly significant difference post hoc test (Prism, V 4.0; GraphPad,
San Diego, CA, USA) were used. All results and figures are pre-
sented as means± SE of the mean. Statistical significance is stated
for p values <0.05.
RESULTS
FUNCTIONAL RECOVERY
The post-lesion recovery process was overshadowed by the appear-
ance of signs of spasticity in the forelimb ipsilateral to the lesion.
The first signs involved clenching of the paw and especially pro-
nounced wrist flexion that appeared 2 weeks post-injury. Post hoc
analysis indicated that these signs of spasticity occurred in ani-
mals in all treatment groups. However, by 6 weeks, only 12% of
rats (2 out of 16) in the control treatment group showed abnormal
wrist flexion and clenching of the paw. This stood in contrast to
60% (3 out of 5) of rats that were injected with scAAV-BDNF and
72% (13 out of 18) of rats belonging to the FULL treatment group
(involving cell grafts expressing BDNF and NT-3 in the lesion site
and scAAV-BDNF expression caudal to lesion) and three out of
seven rats (43%) in the GRAFT/NT-3 group which received the
cell grafts expressing BDNF and NT-3 in the lesion site and scAAV-
NT-3 only expression caudal to lesion. In the, GRAFT/ChABC
group, consisting of cell grafts expressing BDNF and NT-3 and
ChABC injection, only one out of five rats (20%) displayed signs
of spasticity. These effects made further functional testing difficult.
Rats with these signs of spasticity were unable to plantar step or to
grasp for food pellets. Consequently, because most animals were
unable to retrieve pellets, the single-pellet task had to be aban-
doned entirely. Although rats in all groups attempted to reach for
pellets, a significant decline in the attempt rate was apparent in the
treated groups when compared to their baseline attempt rate mea-
surements (FULL treatment group: 15.4%, scAAV-BDNF group:
35%, GRAFT/NT-3 group: 56.7%; GRAFT/ChABC group: 25.7%,
and control group: 86.7%).
A test capable of quantitatively assessing the deficits in
hand/wrist function was the cylinder test (Figure 1A). When
exploring the wall with their paws, rats showing signs of spasticity
did not use the affected limb to explore, significant deficits were
observed in the group receiving scAAV-BDNF only (3.5± 1.3), in
the group receiving graft expressing BDNF/NT-3 and scAAV-NT-
3 expressing vectors (3.4± 1.6), as well as in the FULL treatment
group (2.7± 0.9) when compared to control group (9.4± 1.5)
or the graft expressing BDNF/NT-3 and ChABC treated group
(8.25± 3.4; Figure 1B).
When quantifying the forelimb deficits using a forelimb score
[Ref. (19); a score of 0 indicates no forelimb function and 20 indi-
cates no deficit] rats in the group receiving scAAV-BDNF only
performed somewhat worse than control treated rats (9.2± 0.6
vs. 11.2± 0.8); however this difference was not found to be sta-
tistically significant. When controls were compared to the rats
receiving the FULL treatment with markedly more cells expressing
BDNF (due to the graft) a significant decrease in the performance
was found (7.3± 0.5; p= 0.0008; data not shown).
A test that dramatically illustrates the inability to open the paw
and the rigidity of the wrist flexors in these rats is the grip strength
test (Figure 2A). By sliding the paw over the bar of the force sensor,
the paw basically “hooked” onto the bar and the animal could be
pulled away from the sensor in order to measure the force needed
to overcome flexion and to release the bar. When comparing these
forces between the groups for the unaffected arm (contralateral to
the lesion), no differences were found. This is of interest consider-
ing that a potential neuro-excitatory effect of BDNF could spread
over the entire spinal cord. Because the values were comparable
between all groups, an average value from all animals (118.2± 4 g)
is indicated in Figure 2B as “normal” grip strength.
When testing the affected limb we found that control ani-
mals with hemisection lesion (and no treatment) usually exert
a moderate to weak resistance when being pulled away from the
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bar. The force necessary before releasing/sliding the affected paw
over the bar was significantly lower than that for the unaffected
paw(s) (60.1± 31.5 vs. 118.2± 4 g; p= 0.022). In contrast, rats
with signs of spasticity were hardly able to release the bar resulting
in higher values than those in the unaffected paw and significantly
higher than the control treated rats on the affected side (scAAV-
BDNF vs. Control p= 0.0057; FULL vs. Control p= 0.0001;
scAAV-BDNF vs. GRAFT/NT-3 p= 0.048; FULL vs. GRAFT/NT-
3 p= 0.001; FULL vs. GRAFT/ChABC p= 0.012). Rats receiv-
ing only scAAV-BDNF were statistically indiscernible from those
receiving the full treatment (144.2± 35.6 vs. 157.2± 15.6) as both
had abnormally high “grip” strength. Whereas the GRAFT/NT-3
treated group (76.7± 10.1 g) was not different from the CON-
TROL (60.1± 31.5 g), or the GRAFT/ChABC treated group
(73.5± 10.2 g).
In summary, during normal activities, the majority of rats
receiving scAAV-BDNF only or in combination with other treat-
ments were unable to extend their wrist or open the digits of
their paw. Further, the average force needed to overcome the wrist
flexion was significantly increased.
This unexpected treatment-induced motor deficit, likely related
to BDNF over-expression by cell grafts and spinal scAAV injec-
tion, did not allow the continuation of the originally planned
experiment, and consequently, the focus shifted to the possible
role of BDNF in the development of spasticity. Therefore, histo-
logical results are only reported for serotonergic fibers because of
serotonin’s neuro-excitatory properties and potential role in the
development of spasticity.
Because of the involvement of BDNF in nociception (21), the
Hargreaves apparatus was used to analyze the possible treatment
effect on the latency of injured forelimb withdrawal in response to
a painful stimulus pre and post treatment. Only two groups, FULL
and the GRAFT/NT-3, showed a significant reduction in latency of
withdrawal of their preferred forelimb (p value: 0.016 and 0.038,
respectively), indicating thermal hypersensitivity, in response to
thermal stimulation when compared to baseline latency values
(FULL: 9.0 vs. 11.4 s, GRAFT/NT-3 9.5 vs. 11.4 s). Other treat-
ment groups did not show any significant change in withdrawal
latency following lesion (data not shown). These results do indi-
cate that within our experiment there was no obvious link between
changes in nociception and the occurrence of spasticity-like symp-
toms. The lack of effects on thermo-sensitivity in some of the
groups where BDNF was over-expressed could be based on var-
ious factors including effects of other treatment components or
insufficient BDNF levels.
ANIMAL WEIGHTS
Because earlier findings indicate that BDNF reduces weight gain
in rats (22, 23), decreased weight in the groups of animals
receiving scAAVs expressing BDNF or a combination of grafts
expressing BDNF and scAAVs expressing BDNF, might be one
potential indicator for adverse effects of increased BDNF levels
(Figure 3A).
When we compared the animal weights at the end of the exper-
iment (i.e., 9 weeks post-injury) between the control rats that
received a lesion and GFP expressing scAAV vectors (207± 1.7 g)
and those that received only scAAV-BDNF (201± 1.1 g), we found
FIGURE 3 | Brain-derived neurotrophic factor application influences
weight gain (A). Although baseline weight measurements were not
statistically different between the treatment groups (not shown), after
9 weeks of recovery, the control group had gained significantly more weight
than the FULL treatment group. Animals that received only scAAV-BDNF
but no cell graft BDNF had moderate weight gain and were not significantly
different from either group (A). (B) Shows a representative example of a
horizontal section through a lesion site with cell graft (left; indicated by an X)
and without (right). Micrographs were taken at 100× magnification. There
was no difference in lesion size among the groups (C). *p<0.05.
a small, non-statistically significant decrease in weight gain. Rats
that received the FULL treatment (which entails, among others,
BDNF and NT-3 expressing cell grafts in addition to the injection
of scAAV-BDNF) showed a significant difference (192± 2.3 g).
GRAFT/NT-3 and GRAFT/ChABC treated group was not statisti-
cally different from any other treatment groups. However, it has to
be kept in mind that this weight loss might have also been influ-
enced by other treatment components such as rolipram injections
in addition to the chronic BDNF over-expression by either the
fibroblast cell graft or scAAV vectors.
LESION SIZES
Lesion sizes were analyzed from reconstruction of serial sections
(Figures 3B,C). Following our exclusion criteria, animals with
lesions deviating from a complete hemisection by >10% were
removed from this study (n= 4); a comparison of the lesion
sizes between the groups showed no statistical difference between
either group. The control group had only 2.2% (±1.1) tissue
spared in comparison to 4.1% (±2.8) in the scAAV-BDNF only
group, 1.1% (±1.4) in the FULL treatment group, 3.7 (±0.01) in
the GRAFT/NT-3 group, or 4.12 (±0.01) in the GRAFT/ChABC
group. Thus, variations in lesion size were only minor, and
differences in functional outcome can therefore confidently be
attributed to the different treatments.
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SPROUTING OF SEROTONERGIC FIBERS
Nine weeks after SCI, the density of 5-HT positive fibers both
immediately rostral and caudal to the lesion site was quantified
in order to visualize and compare the possible role of 5-HT fiber
sprouting in the observed spasticity following SCI (Figure 4A).
The integrated density of 5-HT fibers was compared among all
groups (Figure 4B). The highest values for 5-HT were observed in
the GRAFT/NT-3 group (2923± 307) which is statistically signif-
icant when compared to the control group (2148± 117) and the
scAAV-BDNF only group 1621± 418 (p= 0.0330, 0.0424, respec-
tively). The average density value in the FULL treatment group was
2354± 212 and 2423± 337 in GRAFT/ChABC (not significant to
controls).
FIGURE 4 | 5-HT fibers do not facilitate treatment-induced spasticity
following SCI. (A) Gray-scale images following 5-HT immunohistology
show a high density of 5-HT fibers immediately rostral to lesion and their
subsequent reduction following SCI caudal to the lesion. (B) Quantification
of integrated 5-HT fiber density rostral and caudal to the lesion does not
indicate significant influence of the BDNF treatment. Data presented as
mean±SEM, *p<0.05.
Caudal to the lesion, 5-HT density was reduced and even
though the FULL treatment group contained significantly more
fibers than the scAAV-BDNF only group (p= 0.034; 1059± 116
vs. 503± 178; respectively),neither group was statistically different
from the control group (863± 68). The FULL treatment group was
however, significantly different from the GRAFT/ChABC group
(1059± 116 vs. 395± 52; p= 0.0339), but not different from
GRAFT/NT-3 group (1059± 116 vs. 739± 229). Thus, it appears
unlikely that differences in the availability of serotonin contributed
to the increase in spasticity of the treated groups.
ANTAGONIZING BDNF
In order to investigate the underlying mechanisms of the observed
increase in spasticity-like symptoms of animals that received
BDNF treatment either by scAAV vector expression or in com-
bination with grafts expressing BDNF, we quantified the muscle
activity elicited by overcoming the wrist flexion before and after
the spinal injection of the BDNF antagonist TrkB-Fc.
Before injection of TrkB-Fc into the lesion site, wrist flexion was
manually overcome three times in a row with an interval of about
3 s, which was repeated every 10 min following the TrkB-Fc injec-
tion for a total of 30 min. When this experiment was performed in
rats without signs of spasticity (n= 3), there was no resistance to
the stretch and no EMG activity was detected before or during the
extension of the wrist into a horizontal position (i.e., 180°) even
before TrkB-Fc was injected. Therefore, for this experiment only
rats that demonstrated resistance and an EMG response in flexor
muscles to stretching of the wrist (i.e., displayed spasticity-like
symptoms) were included.
When averaging the rectified EMG from all three stretches
and comparing this value to values measured at 10 and 20 min
following a spinal saline injection, we found in four animals
with spasticity-like symptoms (one from the scAAV-BDNF, two
from the FULL treatment group, and one from GRAFT/NT-3
group) only an insignificant decrease in EMG response over time
(Figure 5). Only after 30 min, a significant decline of 11% was
observed.
In contrast, in 10 animals with spasticity-like symptoms
(two scAAV-BDNF and eight of the FULL treatment group)
that received the BDNF antagonist injection, the EMG response
dropped by 51± 9.8% starting as early as 10 min after TrkB-Fc
injection and continued to decline to 64± 8.4% at 20 min and
80± 6.6% at 30 min. The difference in the stretch induced average
and rectified EMG amplitude at each time point was statistically
significant between saline and TrkB-Fc injected rats (Figure 5).
Interestingly, a significant effect of TrkB-Fc was also found in
one out of two control treated rats that showed severe wrist flex-
ion/spasticity,at 20 and 30 min post injection (p= 0.024 and 0.036,
respectively).
DISCUSSION
Brain-derived neurotrophic factor is a prominent neurotrophic
factor with a long history and a variety of effects. Such effects
include the modulation of cell survival (ranging from protec-
tion to cell death), the enhancement of neurite outgrowth and
axonal regeneration, the promotion of myelination, as well as
the modulation of synaptic transmission, the post-injury immune
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FIGURE 5 | Spinal BDNF antagonist reduces resistance to overcome
wrist flexion in animals that exhibit spasticity-like symptoms. EMG
recordings from wrist flexor muscles of the forelimb ipsilateral to the lesion
before and at three different time points following TrkB-Fc injection show a
gradual decline in stretch-evoked EMG responses. Note the relative
inactivity in the recording before and in between the stretch-evoked bursts
(A). When quantifying the EMG response and normalizing it to the values
found in control animals under anesthesia only (did not receive Saline or
TrkB-Fc injections; dotted line) we found a significant drop in EMG response
at 10 min, and a continuous decline over the next 20 min when TrkB-Fc
infusion was compared to saline injections (B). #Indicates a significant
reduction of EMG response at 30 min post saline injection when compared
to control animals that were under anesthesia only (dotted line; p=0.0286).
White columns represent rats that received saline, black columns represent
rats that received the BDNF antagonist. Bars show means±SEM;
*p<0.05. **p< 0.005. Dashed lines indicate the SEM for control
anesthesia (dotted line).
response and neuronal excitability [reviewed in Ref. (8)]. Not sur-
prisingly, BDNF also frequently makes it onto the list of potential
SCI treatments [e.g., Ref. (11, 24–30)]. Considering the broad
effects of BDNF, it is also not surprising that the mechanisms
by which BDNF influences functional outcomes is sometimes
difficult to discern. Understanding the mechanism by which a
treatment influences functional recovery (or decline) is more chal-
lenging when several treatments are combined. A good example
of this can be found in a recent report by Lu and colleagues
(11), where a combined treatment not only resulted in enhanced
plasticity of various descending fiber systems (e.g., serotonergic
fibers) and axonal regeneration, but also in an undesired effect
(i.e., increased occurrence of spasticity). Obviously it is of utmost
importance to explore whether the increased spasticity was due
to treatment-mediated augmentation of neurite growth and plas-
ticity and/or possibly through an acute neuro-excitatory effect of
BDNF (31, 32).
Another challenge of using BDNF for treating SCI is its well-
established role in affecting sensory and nociceptive pathways
in the spinal cord (21) and its ability to modulate glutamate
receptors and sensitization (33, 34). Thus, a possible link between
the observed spasticity-like symptoms found in the present study
and neuropathic pain could be suggested. Yet, in this study no con-
sistent change was found in thermo-sensitivity and it is unlikely
that the signs of spasticity are related to increased pain. For exam-
ple, it could be assumed that when assessing the grip strength,
increased pain sensitivity would result in a withdrawal rather than
an increase in grip strength.
Another potential mechanism involved in promoting spas-
ticity could be aberrant serotonergic sprouting and the subse-
quent increased levels of serotonin, which could increase neuronal
excitability (35, 36). In the current study, we did not find sig-
nificant differences in the serotonergic innervation between the
groups and demonstrate that a BDNF antagonist reduces spastic-
ity within minutes. This indicates that an acute neuro-excitatory
effect of permanent BDNF expression underlies the increase in
signs of spasticity. The relatively fast effect of the TrkB antago-
nist also indicates that, although baseline activity in the flexed
muscle was very low, a contracture [shortening of the mus-
cle; Ref. (37)] was not involved in the observed spasticity-like
symptoms.
It has to be kept in mind that spasticity-like symptoms were also
observed in a small percentage of rats with spinal hemisection that
received only GFP expressing viral vectors. It appears as though
the continuous BDNF over-expression exacerbated this naturally
occurring process by decreasing the threshold for the development
of spasticity. Curiously, the application of the BDNF antagonist
also reduced the spasticity in one control treated rat, indicating
that BDNF signaling might also be involved in post-injury regula-
tion of neuronal excitability. Indeed, increases in BDNF expression
after SCI have been reported (38–40), which can contribute to
increased neuronal excitability by reducing the amount of current
required to reach threshold [i.e., rheobase; Ref. (41, 42)].
There are many possible mechanisms by which BDNF can exert
its excitatory effects. For example, BDNF may increase calcium
and sodium influx through TrkB signaling (43). Furthermore,
activation of the TrkB-PLC pathway may raise the membrane
potential through calcium-mediated channel opening (44). BDNF
has also been reported to down-regulate the potassium-chloride
co-transporter KCC2 (45), which down-regulates the inhibitory
influence of gamma-aminobutyric acid (GABA) receptors. The
most rapid and potent excitatory effects of BDNF, however, have
been shown to involve Nav1.9, on a time scale similar to the action
of glutamate (32).
Considering its neuro-excitatory properties, it is not surprising
that over-expression of BDNF can also promote beneficial effects
without promoting neuronal survival or regeneration. For exam-
ple, Boyce et al. (41), showed that the injection of BDNF expressing
vectors improved locomotor function in rats with complete spinal
cord transections.
Effects of BDNF on synaptic connectivity have been described
in dissociated cultures of early embryonic hippocampal neurons,
where it increased the number of functional synaptic connections
(46). At the same time, studies of long-term effects of BDNF in
dissociated cortical cultures have suggested that BDNF decreases
neuronal firing rate by reducing the strength of all excitatory inputs
onto a given neuron (47). Bolton et al. (48) found that actions of
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BDNF underlying the increase in activity, involved enhancement
of both excitatory and inhibitory synaptic transmission in parallel,
but via distinct cellular mechanisms.
In the current study, it can only be speculated which neuronal
population(s) responded to the BDNF antagonist, since the stretch
induced spasticity-like reflex was decreased. From earlier stud-
ies (31, 49) it is likely that motoneurons play a major role in
the development of spasticity. Generally speaking, following the
administration of the BDNF antagonist we found a decline in
EMG amplitude (see Figure 5 at 20 min) and a decline in burst
duration in parallel to the decline in spasticity-like symptoms.
This is in line with the idea that after SCI spasticity is related to
the re-occurrence of plateau potentials in motoneurons allowing
activity beyond the time of depolarization (49, 50).
In conclusion, although the permanent expression of BDNF
using viral vectors may well promote certain aspects of recovery
through neuro-excitatory mechanisms, the potential side effects
would caution such application and point to the use of regulated
expression systems to control BDNF expression (14). The general
involvement of the TrkB receptor in the development of spasticity
warrants further exploration.
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